HK1017852A1 - Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters - Google Patents

Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Info

Publication number: HK1017852A1
Authority: HK; Hong Kong
Prior art keywords: fatty acid; acid esters; aqueous suspensions; hydroxyrisperidone fatty; hydroxyrisperidone
Prior art date: 1996-05-20

Application number

HK99102949A

Other languages

English (en)

Inventor

Marc Karel Jozef Francois

Roger Carolus August Embrechts

Herman Karel Borghijs

Johan Monbaliu

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-20

Filing date

1999-07-10

Publication date

1999-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1017852(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-07-10 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1999-12-03 Publication of HK1017852A1 publication Critical patent/HK1017852A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

HK99102949A 1996-05-20 1999-07-10 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters HK1017852A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP96201429		1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en)	1996-05-20	1997-05-12	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (1)

Publication Number	Publication Date
HK1017852A1 true HK1017852A1 (en)	1999-12-03

Family

ID=8224016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK99102949A HK1017852A1 (en)	1996-05-20	1999-07-10	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Country Status (38)

Country	Link
US (1)	US6077843A (sk)
EP (1)	EP0904081B1 (sk)
JP (1)	JP3274687B2 (sk)
KR (1)	KR100358373B1 (sk)
CN (1)	CN1093762C (sk)
AR (1)	AR007194A1 (sk)
AT (1)	ATE208619T1 (sk)
AU (1)	AU715572B2 (sk)
BG (1)	BG62684B1 (sk)
BR (1)	BR9706824B8 (sk)
CA (1)	CA2236691C (sk)
CY (2)	CY2270B1 (sk)
CZ (1)	CZ291284B6 (sk)
DE (2)	DE69708284T2 (sk)
DK (1)	DK0904081T3 (sk)
EA (1)	EA000536B1 (sk)
EE (1)	EE03594B1 (sk)
ES (1)	ES2167745T3 (sk)
FR (1)	FR11C0035I2 (sk)
HK (1)	HK1017852A1 (sk)
HR (1)	HRP970276B1 (sk)
HU (2)	HU224025B1 (sk)
ID (1)	ID16927A (sk)
IL (1)	IL124551A (sk)
LU (1)	LU91842I2 (sk)
MX (1)	MX9804816A (sk)
MY (1)	MY126302A (sk)
NO (2)	NO315931B1 (sk)
NZ (1)	NZ330369A (sk)
PL (1)	PL188309B1 (sk)
PT (1)	PT904081E (sk)
SI (1)	SI0904081T1 (sk)
SK (1)	SK284013B6 (sk)
TR (1)	TR199800923T2 (sk)
TW (1)	TW487572B (sk)
UA (1)	UA61898C2 (sk)
WO (1)	WO1997044039A1 (sk)
ZA (1)	ZA974331B (sk)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1056443B1 (en) *	1998-02-25	2004-05-06	Abbott Laboratories	Butorphanol sustained release formulations
AU5489299A (en) *	1998-08-18	2000-03-14	Sepracor, Inc.	Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
PL198797B1 (pl)	1999-03-31	2008-07-31	Janssen Pharmaceutica Nv	Zastosowanie wstępnie żelowanej skrobi
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
NZ524554A (en) *	2000-08-14	2005-07-29	Teva Pharma	Preparation of risperidone
US7666445B2 (en) *	2000-10-20	2010-02-23	The Trustees Of The University Of Pennsylvania	Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) *	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
ES2293039T3 (es) *	2002-07-29	2008-03-16	Alza Corporation	Procedimiento y formas de dosificacion para el suministro controlado de paliperidona.
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) *	2003-10-01	2003-11-05	Novartis Ag	Organic compounds
PL1675573T4 (pl)	2003-10-23	2016-04-29	Otsuka Pharma Co Ltd	Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
US8329203B2 (en) *	2004-01-12	2012-12-11	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
US8221778B2 (en) *	2005-01-12	2012-07-17	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
US20080305140A1 (en) *	2004-01-12	2008-12-11	University Of Pennsylvania	Long-Term Delivery Formulations and Methods of Use Thereof
ES2245252B1 (es) *	2004-06-15	2007-03-01	Farmalider, S.A.	Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
CN101163702B (zh)	2005-04-25	2011-09-07	詹森药业有限公司	制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
PL116330U1 (en)	2005-10-31	2007-04-02	Alza Corp	Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7682356B2 (en)	2006-08-09	2010-03-23	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies for use therein
BRPI0809837A2 (pt) *	2007-04-19	2014-11-11	Youxin Li	"composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
PL2157967T3 (pl)	2007-04-23	2013-06-28	Intarcia Therapeutics Inc	Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
US20090076035A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched paliperidone
US9439906B2 (en) *	2007-12-19	2016-09-13	Janssen Pharmaceutica Nv	Dosing regimen associated with long acting injectable paliperidone esters
US20090209757A1 (en) *	2008-01-10	2009-08-20	Santiago Ini	Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
JP5744735B2 (ja)	2008-09-04	2015-07-08	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	非水性担体を用いた徐放性製剤
NZ747990A (en)	2009-09-28	2020-06-26	Intarcia Therapeutics Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
BR112012010195A2 (pt)	2009-10-30	2016-04-26	Janssen Pharmaceutica Nv	regime de dosagem associado a ésteres de paliperidona injetável de longa ação
WO2011074017A1 (en) *	2009-12-17	2011-06-23	Alkem Laboratories Ltd.	A novel process for the preparation of paliperidone
TWI577377B (zh)	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
CN107625728A (zh)	2010-10-18	2018-01-26	大日本住友制药株式会社	注射用缓释制剂
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8940749B2 (en) *	2011-05-31	2015-01-27	Ramamohan Rao Davuluri	Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydor-9-hydroxy-2-methyl-4H-pyrido[ 1, 2-A]-pyrimidin-4-one(paliperidone) and paliperidone palmitate
WO2013046225A2 (en) *	2011-08-10	2013-04-04	Glenmark Generics Limited	Process for the preparation of paliperidone palmitate
CN102993200B (zh) *	2011-09-10	2016-02-03	鲁翠涛	帕潘立酮氨基酸酯及其制备方法
EP3610890A1 (en)	2012-11-14	2020-02-19	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RS60510B1 (sr)	2015-04-07	2020-08-31	Janssen Pharmaceuticals Inc	Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem
CA2987766A1 (en)	2015-06-03	2016-12-08	Intarcia Therapeutics, Inc.	Implant placement and removal systems
TWI754643B (zh)	2016-05-16	2022-02-11	美商因塔希亞治療公司	升糖素受體選擇性多肽和彼之使用方法
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
EP3565580B1 (en)	2017-01-03	2024-03-06	i2o Therapeutics, Inc.	Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
PL4025187T3 (pl)	2020-11-30	2024-04-29	Janssen Pharmaceutica Nv	Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
DK4025189T3 (da)	2020-11-30	2024-06-10	Janssen Pharmaceutica Nv	Doseringsskemaer i forbindelse med Injicerbare paliperidonformuleringer med forlænget frigivelse
DK4005555T3 (da)	2020-11-30	2024-05-27	Janssen Pharmaceutica Nv	Fremgangsmåder til at sikre resuspension af paliperidonpalmitat-formuleringer
CA3203566A1 (en)	2020-11-30	2022-06-02	Janssen Pharmaceutica Nv	Dosing regimens associated with extended release paliperidone injectable formulations
HUP2100259A1 (hu)	2021-07-07	2023-01-28	Richter Gedeon Nyrt	Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (en)	2021-08-20	2023-02-23	Janssen Pharmaceutica Nv	Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5158952A (en) *	1988-11-07	1992-10-27	Janssen Pharmaceutica N.V.	3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) *	1988-11-07	1999-01-26	Cornelus G. M. Janssen	3-piperidinyl-1,2-benzisoxazoles
US5254556A (en) *	1988-11-07	1993-10-19	Janssen Pharmaceutica N.V.	3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) *	1993-04-28	1999-12-11	Janssen Pharmaceutica Nv	Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
AU684324B2 (en) *	1993-11-19	1997-12-11	Alkermes Controlled Therapeutics Inc. Ii	Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) *	1993-11-19	1997-07-22	Alkermes Controlled Therapeutics Inc. Ii	Preparation of biodegradable microparticles containing a biologically active agent
WO1995013814A1 (en) *	1993-11-19	1995-05-26	Janssen Pharmaceutica N.V.	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
WO1996039405A1 (en) *	1995-06-06	1996-12-12	Hoechst Marion Roussel, Inc.	Pyridiniminyl-1,2-benzisoxazoles and- benzisothiazoles as antipsychotic agents
US5792477A (en) *	1996-05-07	1998-08-11	Alkermes Controlled Therapeutics, Inc. Ii	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 EP EP97923912A patent/EP0904081B1/en not_active Expired - Lifetime
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en active IP Right Grant
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko active IP Right Review Request
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
1999
- 1999-07-10 HK HK99102949A patent/HK1017852A1/xx not_active IP Right Cessation
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I1/el unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active

Also Published As

Publication number	Publication date
CA2236691C (en)	2007-01-02
EE03594B1 (et)	2002-02-15
CN1093762C (zh)	2002-11-06
TW487572B (en)	2002-05-21
HUS1100013I1 (hu)	2017-03-28
MY126302A (en)	2006-09-29
CA2236691A1 (en)	1997-11-27
DE122011100027I1 (de)	2011-11-17
UA61898C2 (en)	2003-12-15
TR199800923T2 (xx)	1999-09-21
DE69708284D1 (de)	2001-12-20
NO981984D0 (no)	1998-04-30
KR100358373B1 (ko)	2003-02-11
HRP970276B1 (en)	2002-04-30
HRP970276A2 (en)	1998-04-30
NZ330369A (en)	2000-04-28
HUP9901319A2 (hu)	1999-08-30
BG62684B1 (bg)	2000-05-31
SK284013B6 (sk)	2004-08-03
NO981984L (no)	1998-11-19
MX9804816A (es)	1998-10-31
JP3274687B2 (ja)	2002-04-15
EA199800531A1 (ru)	1998-12-24
ATE208619T1 (de)	2001-11-15
AU2955997A (en)	1997-12-09
IL124551A0 (en)	1998-12-06
ZA974331B (en)	1998-11-19
SK62098A3 (en)	2000-04-10
CY2011011I2 (el)	2016-12-14
DK0904081T3 (da)	2002-02-25
KR19990067603A (ko)	1999-08-25
EA000536B1 (ru)	1999-10-28
WO1997044039A1 (en)	1997-11-27
PT904081E (pt)	2002-04-29
NO2011015I1 (no)	2011-09-19
FR11C0035I1 (sk)	2011-07-10
BR9706824A (pt)	1999-03-23
PL188309B1 (pl)	2005-01-31
BR9706824B8 (pt)	2015-02-18
JP2000513718A (ja)	2000-10-17
IL124551A (en)	2001-08-26
BG102443A (en)	1999-06-30
HU224025B1 (hu)	2005-05-30
US6077843A (en)	2000-06-20
FR11C0035I2 (fr)	2013-08-16
CZ140198A3 (cs)	1999-04-14
ES2167745T3 (es)	2002-05-16
PL327995A1 (en)	1999-01-04
CZ291284B6 (cs)	2003-01-15
ID16927A (id)	1997-11-20
CN1206347A (zh)	1999-01-27
NO315931B1 (no)	2003-11-17
EP0904081A1 (en)	1999-03-31
AR007194A1 (es)	1999-10-13
LU91842I2 (fr)	2011-09-20
EP0904081B1 (en)	2001-11-14
DE69708284T2 (de)	2002-07-25
HUP9901319A3 (en)	1999-11-29
SI0904081T1 (en)	2002-04-30
EE9800136A (et)	1998-10-15
AU715572B2 (en)	2000-02-03
CY2270B1 (en)	2003-07-04
NO2011015I2 (no)	2013-03-11
CY2011011I1 (el)	2016-12-14

Publication	Publication Date	Title
CY2270B1 (en)	2003-07-04	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
AP2000001809A0 (en)	2000-06-30	Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
PL331700A1 (en)	1999-08-02	Method of obtaining fatty acid esters
GB9403857D0 (en)	1994-04-20	Fatty acid derivatives
GB9508023D0 (en)	1995-06-07	Fatty acid derivatives
IL115594A0 (en)	1996-01-19	Preparation of alpha-tertiary carboxylic acid esters
IL122919A0 (en)	1998-08-16	Preparation of 1-alkyl-pyrazole-5-carboxylic acid esters
HK49897A (en)	1997-04-25	Process for preparation of lower fatty acid ester
GB9517107D0 (en)	1995-10-25	Fatty acid esters
SG28202A1 (en)	1996-04-01	Fatty acid derivatives
ZA9586B (en)	1995-07-20	New sulfuric acid esters of sugar alochols

Legal Events

Date	Code	Title	Description
2004-12-15	PF	Patent in force
2017-05-26	PE	Patent expired	Effective date: 20170511